Home › Funds › WESTFIELD CAPITAL MANAGEMENT CO LP › RYTM

WESTFIELD CAPITAL MANAGEMENT CO LP position in RYTM

RHYTHM PHARMACEUTICALS INC · Health Care

WESTFIELD CAPITAL MANAGEMENT CO LP reported holding 2,480,692 shares of RYTM (RHYTHM PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$236.2M, representing 0.77% of its reported portfolio and ranking #25 among its reported holdings. WESTFIELD CAPITAL MANAGEMENT CO LP has disclosed RYTM holdings in 7 of the last 7 reported quarters, going back to Q1 2025.

Latest position (Q3 2026)2.48M sh
Reported value held$236.20M
Portfolio Weight0.77%
First reportedQ1 2025
Last changeAdd
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How WESTFIELD CAPITAL MANAGEMENT CO LP's RYTM position evolved

WESTFIELD CAPITAL MANAGEMENT CO LP first disclosed a stake in RYTM in Q1 2025 at 1,341,092 shares (US$71.0M). The position peaked in Q2 2026 at 2,208,595 shares, worth US$245.2M. Across 7 filings, WESTFIELD CAPITAL MANAGEMENT CO LP increased the stake 5 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 2,480,692 shares valued at US$236.2M — an increase of 272,097 shares quarter over quarter.. Notable position changes include a 34% trim in Q3 2025 (shares rose 6% over the following quarter), a 52% increase in Q1 2026 (shares rose 28% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q1 2025 1.34M $71.04M New
Q2 2025 1.63M $102.97M Add
Q3 2025 1.07M $107.96M Reduce
Q4 2025 1.27M $135.64M Add
Q1 2026 1.93M $167.78M Add
Q2 2026 2.21M $245.22M Add
Q3 2026 2.48M $236.20M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About RYTM and 13F data

RYTM (RHYTHM PHARMACEUTICALS INC) is a Health Care company. 42 other funds we track also report a position in RYTM — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$740.2M), BAKER BROS. ADVISORS LP (US$622.3M), PERCEPTIVE ADVISORS LLC (US$287.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding RYTM

All RYTM fund holders →

FAQ

How long has WESTFIELD CAPITAL MANAGEMENT CO LP held RYTM?

WESTFIELD CAPITAL MANAGEMENT CO LP has disclosed RYTM holdings in 7 of the last 7 reported quarters, going back to Q1 2025.

What is WESTFIELD CAPITAL MANAGEMENT CO LP's current position in RYTM?

As of Q3 2026, WESTFIELD CAPITAL MANAGEMENT CO LP holds 2.48M shares of RYTM (RHYTHM PHARMACEUTICALS INC), valued at $236.20M, representing 0.77% of its reported portfolio and ranking #25.

Has WESTFIELD CAPITAL MANAGEMENT CO LP been buying or selling RYTM?

In the latest 13F filing (Q3 2026), WESTFIELD CAPITAL MANAGEMENT CO LP increased its position in RYTM. The position peaked in Q2 2026 at 2.21M shares.

Which other funds hold RYTM?

Other major institutional holders of RYTM include RA CAPITAL MANAGEMENT, L.P., BAKER BROS. ADVISORS LP, PERCEPTIVE ADVISORS LLC, among 42 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.